$1.27
-0.10-7.3%
Last update: Nov 5, 9:08 AM
Aptevo Therapeutics Inc (APVO) Stock Price, Quote, News & History
APVONASDAQ
Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.
You can purchase shares of Aptevo Therapeutics (NASDAQ:APVO) through any online brokerage.
Other companies in Aptevo Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Aptevo Therapeutics has a consensus price target of $106560.00.
The stock price for Aptevo Therapeutics (NASDAQ: APVO) is $1.37 last updated November 5, 2026 at 9:08 AM EST.
There are no upcoming dividends for Aptevo Therapeutics.
Aptevo Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Aptevo Therapeutics.
Aptevo Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which...
